

# RECEIVED CENTRAL FAX CENTER

MAY 1 2 2006

Fax

, and a second s		Company	Fax	Phone
		USPTO	571-273 <b>-</b> 8300	
From	Kerri Pollard Sch	ray	Number of Pages	5
Date	May 12, 2006		Client Number	2006636-0011
Phone	(617) 248-4831		Operator	Tīme Sent

#### Comments

Return by

Inter-office Mail

Hold for pick-up

4080700\_1.DOC

This Message is transmitted to you by the law firm of Choate, Hall & Stewart LLP. The substance of this message, along with any attachments, may be confidential and legally privileged. If you are not the designated recipient of this message, please destroy it and notify the sender of the error by return e-mail or by calling 1-800-520-2427.

Under regulations of the Treasury Department, we are required to include the following statement in this message: Any advice contained herein (or in any attachment hereto) regarding federal tax matters was not intended or written by the sender to be used, and it cannot be used by any taxpayer, for the purpose of avoiding penalties that may be imposed on the taxpayer.

For more information about Choate, Hall & Stewart LLP, please visit us at www.choate.com

Two International Place I Boston MA 02110 I t 617-248-5000 I f 617-248-4000 I choate.com

RECEIVED **CENTRAL FAX CENTER** 

### MAY 12 2006

# ATTORNEY DOCKET NO.: 2006636-0011

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Alvarez, et al.

Examiner:

Serial No:

10/522,810

Group Art Unit: 1646

Filing Date: Corresp. to:

September 20, 2005 PCT/US03/17411

Title:

Int. Filing Date: June 2, 2003 Treatment of Cell Proliferative Disorders with Chlorotoxin

#### Via Facsimile Transmission

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

#### **TRANSMITTAL**

Enclosed herewith please find the following:

1. Request for Change of Attorney Docket Number and Correspondence Address (1 page);

2. Power of Attorney to Prosecute Applications Before The USPTO (1 page); and

3. Statement Under 37 C.F.R. 3.73(b) (1 page).

Additionally, please charge any further fees associated with this filing or apply any credits to our Deposit Account No. 03-1721.

Respectfully submitted,

Kerri Pollard Schray, Ph.D.

Reg. No. 47,066

Choate, Hall & Stewart LLP Two International Place Boston, MA 02110 Telephone: (617) 248-5000 Facsimile (617-248-4000

Dated: May 12, 2006

4080703\_1.DOC

Certificate of Facsimile Transmission								
hereby certify that this paper is being facsimile transmitted to the Commissioner for eatents, P.O. Box 1450, Alexandria, VA 22313-1450 (571-273-8300).  5-12-06 Signature								

Sandra Saccocia

Typed or Printed Name of person signing certificate

#### ATTORNEY DOCKET No.: 2006636-0011

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Alvarez, et al.

Examiner:

RECEIVED

Serial No:

10/522,810

Group Art Unit: 1646

CENTRAL FAX CENTER

Filing Date: Corresp. to:

September 20, 2005 PCT/US03/17411

MAY 1 2 2006

Int. Filing Date: June 2, 2003

Title:

Treatment of Cell Proliferative Disorders with Chlorotoxin

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

# REQUEST FOR CHANGE OF ATTORNEY DOCKET NUMBER AND CORRESPONDENCE ADDRESS

Please change the Attorney Docket Number and Correspondence address for the above captioned patent application as follows:

- Change Attorney Docket Number from 051530-5008 US to 2006636-0011 Ι.
- All correspondence should be sent to Customer Number 24280: 2.

Choate, Hall & Stewart Patent Department Attn: Kerri Pollard Schray, Ph.D. Two International Place Boston, MA 02110

Please direct all telephone calls to Kerri Pollard Schray at 617-248-4831.

Respectfully Submitted,

Dated: May 12, 2006

Kerri Pollard Schray Registration No. 47,066

CHOATE, HALL & STEWART LLP

Two International Place Boston, MA 02110

Telephone: (617) 248-5000 Facsimile: (617-248-4000

4080554\_1.DOC

Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the Commissioner for Patents, P/Q. Box 1450, Alexandria, VA 22313-1450 (571-

273-8300).

Signature

Sandra Saccocia

PTO/S8/20 (01-06)

Approved for use through 12/31/2008, OMB 0561-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

LIGHT OF THE PROPERTY OF

U.S. Patern and Tracement Unice; U.S. DEFART INVESTOR Commence of U.S. DEFART INVESTOR COMMENCE.

Under the Paperwork Raduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO											
I hereby revoke all previous powers of attorney given in the application identified in the attached statement under											
37 CFR 3.7	73(b)										
i hereby ap											
✓ Practiti	24280										
OR  Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):											
	Name				me	Registration Number					
		Number		<del> </del>							
<del> </del>											
ļ			攌								
<u> </u>				······································							
as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents											
attached to t	URE LOLLY IN SECCOLORINGS MITTING TO LEVE 210/5/2										
Please chan	ge the correspondence address for the applicat	ion identified	in the a	itached stalement und	der 37 CFR 3.73(b) 1	.o:					
The address associated with Customer Number. 24280											
OR											
Firm or Individual Name											
Address											
City		State	:		Zip						
Country											
	Email										
elephone	Telephone										
Applemed No	nne and Address:										
_											
Transmolecular, Inc., 840 Memorial Drive, 2nd Floor, Cambridge, MA 02199											
A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be											
A copy of	this form, together with a statement of the application in which this form is use	d. The sta	temen	t under 37 CFR 3.7	73(b) may be con	pleted by one of					
A copy of this form, together with a statement under 37 CFR 3.73(b) (roll of 1707) and the completed by one of filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of filed in each application in which this form if the appointed practitioners appointed in this form if the appointed practitioners appointed in this form if the appointed practitioners is to be filed.											
and must identify the application in which this Power of Attorney is to so meet											
The individual whose signature and title is supplied below is authorized to act on benair of the assignee											
Signature	I thin Bre		Date 5 2 0 Cp			04					
Name	E. Michael/Egan				Telephone (017	-995-305C					
TWA	Description of CEO										

Title President CEO

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a banefit by the public which is to file (and This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a banefit by the public which is to file (and 57 CFR 1.11) and 1.14. This collection is estimated to take 3 minutes by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes by the USPTO time will vary depending upon the individual case. Any normalized application form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. Any complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. Any complete individual case, and submitted to provide the USPTO. Time will vary depending upon the individual case. Any complete individual case, and submitted to complete the USPTO. Time will vary depending upon the individual case. Any complete individual case, and submitted to provide the use of the USPTO. Time will vary depending upon the individual

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## RECEIVED CENTRAL FAX CHNTERS

MAY 1 2 2006

PTO/\$B/98 (12-05)

PTO/SB/98 (12-05)
Approved for use through 07/31/2096. OMB 0691-0031
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it displays a valid OMB control number. STATEMENT UNDER 37 CFR 3.73(b) Transmolecular, Inc. Applicant/Patent Owner: Filed/Issue Date: June 2, 2003 Application No./Patent No./Control No.: 10/522,810 Treatment of Cell Proliferative Disorders With Chlorotoxin a corporation Transmolecular, Inc. (Type of Assignee: corporation, partnership, university, government agency, etc.) (Name of Assignee) states that it is: 1. The assignee of the entire right, title, and interest; or an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is... in the patent application/patent identified above by virtue of either. A An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 017371 Frame 0872 or a true copy of the original assignment is attached. B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: 1. From: The document was recorded in the United States Patent and Trademark Office at \_, or for which a copy thereof is sittached. \_, Frame Reel To: 2. From: The document was recorded in the United States Patent and Trademark Office at , or for which a copy thereof is attached. \_ Frame Reel Ta: 3. From: The document was recorded in the United States Patent and Trademark Office at , or for which a copy thereof is attached. , Frame Additional documents in the chain of title are listed on a supplemental sheet. As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.081 is supplied below) is authorized to act on behalf of the assignee. The undersigned (whose till 210G Signature 617 995 3050 Egan Telephone Number Printed or Typed Name

This collection of information is required by S7 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to useful processes) an application, confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing his burden, should be sent to the Chief information Officer, U.S. Patent son Trademark Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND TO Commission for Patentia, P.O. Rox 1450, Alexandria, VA 22313-1450. FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.